相关实验视频

Updated: Jul 11, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

针对慢性淋巴细胞白血病的TP53干扰:当前的策略和未来的方向

Stefano Molica¹, Constantine Tam², David Allsup³

¹Queens Centre for Oncology and Haematology, Castle Hill Hospital, Hull University NHS Trust, Hull, UK.

Hematological oncology

|November 8, 2023

概括

在慢性淋巴细胞白血病 (CLL) 中引起p53功能障碍的遗传异常限制了向治疗的有效性. 未来的研究必须解决p53途径,以改善高风险患者的治疗结果.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

在慢性淋巴细胞白血病 (CLL) 中,TP53基因突变和缺失很常见,导致p53通路功能障碍.
目前针对CLL的向疗法没有直接解决p53通路缺陷,导致治疗耐药性和预后不佳.
考虑了p53通路的使用.
研究的目的_研究_目的
主要_方法方法
主要_结果
结论结论结论结论

研究的目的:

审查目前针对慢性淋巴细胞白血病 (CLL) 的p53功能障碍的治疗策略.
突出在CLL治疗中p53异常所带来的挑战.
探索新的治疗方法,以改善高风险的CLL患者与TP53变化的结果.

主要方法:

对TP53突变的CLL治疗策略的文献综述.
对针对p53通路的新兴药物类别的分析.
讨论与现有CLL治疗的组合疗法.

主要成果:

针对TP53突变的CLL,正在研究一些新的治疗策略.
这些药物包括小鼠双分钟2 (MDM2) 抑制剂,p53活性剂,出口因1 (XPO1) 抑制剂以及突变性和Rad3相关性 (ATR) 抑制剂.
这些药物与B细胞受体或B细胞淋巴瘤-2 (BCL-2) 抑制剂的组合显示出有前途.

结论:

解决p53通路功能障碍对于改善CLL治疗结果至关重要.
预计新型p53向剂和组合疗法将影响未来对高风险CLL的临床试验.
恢复p53功能是管理TP53异常CLL的一个关键目标.

关键词:

在 CLL CLL 中.目前的策略与当前的战略.新的治疗方法针对TP53的异常.

更多相关视频

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...